Purple Biotech (PPBT) Long-Term Debt Issuances (2016)

Purple Biotech's (PPBT) quarterly Long-Term Debt Issuances came in at $15670.0 in Q4 2016.

Purple Biotech (PPBT) Long-Term Debt Issuances (2016) Analysis & Trends

Purple Biotech (PPBT) has 1 years of Long-Term Debt Issuances data on file, last reported at $15670.0 in Q4 2016.

On a quarterly basis, Long-Term Debt Issuances changed N/A year-over-year to $15670.0 in Q4 2016; TTM through Dec 2016 was $15670.0, a N/A change from a year earlier, with the FY2017 full-year figure at -$16000.0, down 202.11% from the prior year.
Long-Term Debt Issuances for Q4 2016 stood at $15670.0.
Over the last five years, Long-Term Debt Issuances for PPBT reached as high as $15670.0 in Q4 2016 and fell as low as $15670.0 in Q4 2016.

Peer Comparison

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Long-Term Debt Issuances (Qtr)
1	Oculis Holding AG	68,785.72 Bn	68,785.72 Bn	-	-
2	Nanobiotix	1,895.57 Bn	1,895.51 Bn	-	-
3	BeOne Medicines	471.35 Bn	466.56 Bn	1.35 Bn	-
4	NuCana	279.75 Bn	279.75 Bn	-	-
5	Vertex Pharmaceuticals	120.24 Bn	113.00 Bn	2.59 Bn	-
6	Regeneron Pharmaceuticals	67.80 Bn	59.04 Bn	3.31 Bn	-
7	Belite Bio	62.51 Bn	62.51 Bn	-	-
8	Argenx Se	57.38 Bn	57.38 Bn	1.41 Bn	-
9	Revolution Medicines	37.78 Bn	37.78 Bn	-	-
10	Purple Biotech	1.33 Bn	1.33 Bn	-	-

Historic Data

Download Data

Date	Value
Dec 31, 2016	15,670.00
Dec 31, 2016	15,670.00